Literature DB >> 10199389

Structural characterization of viral neutralizing monoclonal antibodies to hepatitis B surface antigen.

M H Shearer1, C Sureau, B Dunbar, R C Kennedy.   

Abstract

In this study we describe the viral neutralizing activity of murine monoclonal antibodies (MAb) specific for hepatitis B surface antigen (HBsAg). This viral neutralizing activity was assessed in vitro by employing Hepatitis Delta Virus (HDV) and human hepatocytes as target cells. To further characterize these viral neutralizing antibodies we generated a panel of anti-idiotypic (anti-Id) reagents and serologically characterized these antibodies for epitope specificity, Id specificity, and Id heterogeneity. Direct binding and competitive inhibition solid phase enzyme immunoassay have demonstrated that two murine MAb specific for HBsAg (anti-HBs), designated A1.2 and A3.1, recognize similar or overlapping epitopes on HBsAg, while monoclonal anti-HBs, designated A2.1 recognizes a unique HBsAg epitope. Further, Id analysis using monoclonal and polyclonal anti-Id reagents have identified both a private and a cross-reactive Id, respectively, on the anti-HBs, A1.2 preparation. The source of the idiotypic cross-reactivity between A1.2 and A3.1 has been identified, using Western blot analysis, to conformational determinants expressed by the heavy (H) and light (L) chains of these monoclonal anti-HBs. Lastly, the intrastrain antibody repertoire induced following HBsAg immunization was found to be relatively restricted in heterogeneity by clonotype analysis using isoelectric focusing and affinity immunoblot analysis. Interspecies variability in the anti-HBs response was observed based on epitope recognition using purified anti-HBs from a variety of species.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10199389     DOI: 10.1016/s0161-5890(98)00110-2

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

1.  Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines.

Authors:  Rajalakshmi Shanmugham; Nagarajan Thirumeni; Varaprasada Sankarashetty Rao; Vidyasagar Pitta; Saranyarevathy Kasthuri; Nagendrakumar Balasubramanian Singanallur; Rajendra Lingala; Lakshmi Narsu Mangamoori; Srinivasan Alwar Villuppanoor
Journal:  Clin Vaccine Immunol       Date:  2010-06-30

Review 2.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

4.  Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus.

Authors:  Georges Abou Jaoudé; Camille Sureau
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange.

Authors:  Georges Abou-Jaoudé; Camille Sureau
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

6.  A function essential to viral entry underlies the hepatitis B virus "a" determinant.

Authors:  Jessica Salisse; Camille Sureau
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

7.  Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies.

Authors:  Romain Julithe; Georges Abou-Jaoudé; Camille Sureau
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

8.  Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.

Authors:  Anke M Mulder; Bridget Carragher; Victoria Towne; Yuan Meng; Yang Wang; Lance Dieter; Clinton S Potter; Michael W Washabaugh; Robert D Sitrin; Qinjian Zhao
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

9.  Detecting hepatitis B surface antigen mutants.

Authors:  Paul F Coleman
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

Review 10.  NTCP and beyond: opening the door to unveil hepatitis B virus entry.

Authors:  Koichi Watashi; Stephan Urban; Wenhui Li; Takaji Wakita
Journal:  Int J Mol Sci       Date:  2014-02-19       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.